Atossa Therapeutics, Inc. financial data

Symbol
ATOS on Nasdaq
Industry
Pharmaceutical Preparations
Location
10202 5 Th Avenue Ne, Suite 200, Seattle, WA
State of incorporation
DE
Fiscal year end
December 31
Former names
ATOSSA GENETICS INC (to 11/13/2019)
Latest financial report
10-Q - Q3 2024 - Nov 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.53K % -45.3%
Debt-to-equity 6.67 % +87.8%
Return On Equity -32.6 % -18.5%
Return On Assets -30.5 % -15%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 126M shares +0.4%
Common Stock, Shares, Outstanding 125M shares 0%
Entity Public Float 160M USD +15.6%
Common Stock, Value, Issued 22.9M USD +0.4%
Weighted Average Number of Shares Outstanding, Basic 126M shares -0.02%
Weighted Average Number of Shares Outstanding, Diluted 126M shares -0.02%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 16.4M USD -1.82%
General and Administrative Expense 13.1M USD -5.14%
Operating Income (Loss) -29.5M USD +3.33%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -26.9M USD +9.79%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -26.9M USD +9.79%
Earnings Per Share, Basic -0.22 USD/shares +8.33%
Earnings Per Share, Diluted -0.22 USD/shares -20%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 74.8M USD -20.5%
Other Assets, Current 7K USD -96.5%
Assets, Current 77.1M USD -21%
Operating Lease, Right-of-Use Asset 0 USD
Other Assets, Noncurrent 2.37M USD +1.24%
Assets 79.5M USD -21.8%
Accounts Payable, Current 1.56M USD +117%
Employee-related Liabilities, Current 1.06M USD -26.5%
Accrued Liabilities, Current 1.69M USD +34.3%
Liabilities, Current 5.8M USD +68.3%
Liabilities 5.8M USD +68.3%
Accumulated Other Comprehensive Income (Loss), Net of Tax -54K USD
Retained Earnings (Accumulated Deficit) -205M USD -15.1%
Stockholders' Equity Attributable to Parent 73.7M USD -25%
Liabilities and Equity 79.5M USD -21.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -4.7M USD +33.1%
Net Cash Provided by (Used in) Financing Activities 204K USD
Net Cash Provided by (Used in) Investing Activities -6K USD
Common Stock, Shares Authorized 350M shares +100%
Common Stock, Shares, Issued 126M shares +0.4%
Common Stock, Par or Stated Value Per Share 0.18 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -4.5M USD +35.9%
Deferred Tax Assets, Valuation Allowance 24.6M USD +27.5%
Deferred Tax Assets, Gross 24.7M USD +28%
Operating Lease, Liability 0 USD
Depreciation 5K USD +66.7%
Payments to Acquire Property, Plant, and Equipment 6K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -6.23M USD +22.8%
Deferred Tax Assets, Operating Loss Carryforwards 13.3M USD +15.2%
Preferred Stock, Shares Issued 582 shares -41.8%
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 258M USD
Preferred Stock, Shares Outstanding 582 shares -41.8%
Depreciation, Depletion and Amortization 3K USD +50%
Deferred Tax Assets, Net of Valuation Allowance 94K USD +9300%
Share-based Payment Arrangement, Expense 2.04M USD -63.9%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%